普洛药业(000739) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was ¥1,675,316,248.13, representing a 15.86% increase compared to ¥1,445,922,686.96 in the same period last year[3] - Net profit attributable to shareholders for the same period was ¥110,560,349.54, a significant increase of 64.62% from ¥67,162,129.52 year-over-year[3] - Basic earnings per share rose to ¥0.0938, reflecting a 64.56% increase compared to ¥0.057 in the previous year[3] - Total profit rose by 63.43% to ¥135,759,796.21 from ¥83,069,250.05, driven by increased sales revenue and gross margin[9] - Net profit increased by 64.62% to ¥110,560,349.54 from ¥67,162,129.52, attributed to higher sales revenue and gross margin[9] - The total revenue for the first quarter of 2019 was 135,759,796.21 CNY, an increase from 83,069,250.05 CNY in the same period last year, representing a growth of approximately 63.4%[22] - The net profit for the first quarter of 2019 was 110,560,349.54 CNY, compared to 67,162,129.52 CNY in the previous year, indicating a year-over-year increase of about 64.6%[22] - The operating profit for the first quarter was 137,594,789.08 CNY, up from 79,259,955.81 CNY, reflecting a growth of approximately 73.4%[22] - The total comprehensive income for the first quarter was 111,468,880.72 CNY, compared to 66,809,250.16 CNY in the same period last year, marking an increase of approximately 66.8%[23] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥5,718,775,908.70, a slight decrease of 0.56% from ¥5,750,766,279.01 at the end of the previous year[3] - The net assets attributable to shareholders increased by 3.33% to ¥3,455,754,418.47 from ¥3,344,285,537.75 at the end of the previous year[3] - Total liabilities decreased to ¥2,263,021,490.23 from ¥2,406,480,741.26, indicating improved financial stability[15] - The total assets as of March 31, 2019, reached CNY 2,347,473,285.97, compared to CNY 2,320,535,625.88 at the end of 2018, reflecting a growth of approximately 1.2%[20] - The company's total equity attributable to shareholders was CNY 3,455,754,418.47, up from CNY 3,344,285,537.75, indicating an increase of about 3.3%[16] - The total liabilities as of March 31, 2019, were CNY 108,885,218.74, compared to CNY 75,871,460.58, indicating an increase of about 43.5%[19] Cash Flow - The company reported a net cash flow from operating activities of ¥180,356,281.54, which is a decrease of 10.77% compared to ¥202,134,293.38 in the same period last year[3] - The total cash inflow from operating activities was CNY 1,279,208,044.35, a decrease of 22.5% compared to CNY 1,652,298,113.15 in the previous year[28] - The total cash outflow from operating activities was CNY 1,098,851,762.81, down from CNY 1,450,163,819.77, reflecting a reduction of 24.2%[29] - The net cash flow from operating activities was CNY 180,356,281.54, compared to CNY 202,134,293.38 in the previous year, indicating a decline of 10.7%[29] - The cash inflow from investment activities totaled CNY 101,980,946.32, significantly lower than CNY 200,403.07 from the previous year[29] - The cash outflow from investment activities was CNY 93,487,034.16, compared to CNY 31,587,901.16 in the previous year, showing an increase of 195.5%[29] - The net cash flow from financing activities was CNY -177,193,682.96, worsening from CNY -101,021,028.06 in the previous year[30] - The company reported a cash balance of CNY 636,111.19 as of the first quarter of 2019[36] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,237[6] - The largest shareholder, Hengdian Group Holdings Co., Ltd., held 28.08% of the shares, amounting to 330,941,729 shares[6] - The company did not engage in any repurchase transactions during the reporting period[7] Expenses - Total operating costs for Q1 2019 amounted to CNY 1,545,626,437.97, up from CNY 1,368,517,683.62 in the previous year, indicating an increase of about 12.9%[21] - Research and development expenses for Q1 2019 were CNY 72,318,564.80, compared to CNY 68,972,035.45 in the previous year, showing an increase of approximately 4.9%[21] - The company incurred sales expenses of 1,004,592.16 CNY and management expenses of 5,146,952.82 CNY during the quarter[25] - The company reported a decrease in employee compensation liabilities from CNY 3,041,640.59 to CNY 1,389,301.67, indicating a reduction of about 54.4%[19] Other Financial Metrics - Financial expenses decreased by 30.60% to ¥21,074,474.78 from ¥30,368,317.55, reflecting a reduction in interest expenses[9] - Investment income surged by 313.08% to ¥6,263,366.84 from ¥1,516,253.34, mainly due to increased profits from joint ventures[9] - The company reported other comprehensive income after tax of 908,531.18 CNY, compared to a loss of 352,879.36 CNY in the previous year[23] - The company reported an asset impairment loss of 918,557.99 CNY, compared to 117,529.35 CNY in the previous year[22] Audit Status - The first quarter report for 2019 was not audited[37]